Fig. 2: HumAbs inhibition of blood-stage infection.
A Dose response of PvAMA1-specific humAbs against Pf-PvAMA1 transgenic parasites of humAb with lowest IC50s. Each symbol represents the average of three replicates for every concentration. B The mean percentage (± SEM) of reticulocytes infected using Pv clinical isolates in short-term invasion inhibition with different humAbs at 100 μg/mL. Each dot represents a biological replicate from a different clinical isolate (n = 2–7). The flow cytometry background of target cells (reticulocytes) without parasites (mean is 9%, range 5–15% invasion) was subtracted from each experiment. Mouse mAb, 2C3 (100 μg/mL) binds to Duffy antigen on reticulocytes, thus blocking Pv invasion of reticulocytes (positive control) (p-value = 0.9891). Only humAb 826827 significantly inhibited reticulocyte invasion compared to the negative control (p-value = <0.0001). HumAb 043038 was used as a negative control for experiments represented in panel A and B. A multi-variant one-way ANOVA and Tukey’s secondary test was used to calculate the P-values compared to the positive and negative controls using Prism. C Dose response of humAb 826827 against four different Pv clinical isolates in short-term invasion inhibition cultures (Isolate 1, 2, 3, and 4 have IC50s of 39.96, 66.78, 25.22, and 61.04 μg/mL respectively. Note: These are different isolates than those used for Fig. 2B).
